Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0303）

NCT02388919 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

439

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Anlotinib
DRUG: Placebo

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.